Among the companies whose shares are expected to actively trade
in Monday's session are Amylin Pharmaceuticals Inc. (AMLN),
Alkermes Inc. (ALKS) and PharMerica Corp. (PMC).
The U.S. Food and Drug Administration approved Amylin's diabetes
drug Bydureon after a prolonged regulatory process. The drug, which
treats type 2 diabetes, was developed by the company along with its
partner Alkermes. Shares of Amylin surged 16% to $14.06 after
hours, while shares of Alkermes jumped 4.6% to $19.98.
U.S. regulators filed suit Friday to block Omnicare Inc.'s (OCR)
bid for rival PharMerica, claiming that combining the two biggest
nursing-home pharmacies in the U.S. would hurt competition and
raise drug prices. PharMerica shares dropped 9.2% to $12.98, while
Omnicare was off 1.4% at $32.60.
Watch List:
Standard & Poor's Ratings Services lowered its outlook on
Jefferies Group Inc. (JEF) and Cantor Fitzgerald LP to negative
from stable and placed its ratings on GFI Group Inc. (GFIG) on
watch for a possible downgrade, saying it expects the institutional
brokers' operating performance to remain pressured due to prolonged
weakness in the financial markets.
Johnson & Johnson (JNJ) said it is voluntarily recalling
2,200 tubes of Aveeno-brand baby lotion from retailers in the U.S.
Southeast after a sample contained too much of a common type of
bacteria. The company noted that the recall on the lot of Aveeno
Baby Calming Comfort lotion is precautionary and limited to a small
amount of product.
Horizon Lines Inc. (HRZL) agreed to pay $1.5 million to resolve
federal regulators' allegations of improper oil disposal on one of
its Pacific Ocean ships.
Winn-Dixie Stores Inc. (WINN) disclosed its chief financial
officer Bennett L. Nussbaum will step down from that role following
the company's merger with grocery-store operator BI-LO LLC, but
will remain with the company as its integration lead.
-Edited by Maya Pope-Chappell and Ian Thomson; write to
maya.pope-chappell@dowjones.com and ian.thomson@dowjones.com